-
Je něco špatně v tomto záznamu ?
Central Pathology Review in SENTIX, A Prospective Observational International Study on Sentinel Lymph Node Biopsy in Patients with Early-Stage Cervical Cancer (ENGOT-CX2)
K. Nemejcova, R. Kocian, C. Kohler, J. Jarkovsky, J. Klat, A. Berjon, R. Pilka, B. Sehnal, B. Gil-Ibanez, E. Lupo, A. Petiz, OA. Sanchez, P. Kascak, F. Martinelli, A. Buda, J. Presl, M. Barahona, LV. Lonkhuijzen, W. Szatkowski, L. Minar, M....
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Grantová podpora
Project RVO 64165
Ministry of Health, Czech Republic
No 16-31643A
Ministerstvo Zdravotnictví Ceské Republiky
NV19-03-00023
Ministerstvo Zdravotnictví Ceské Republiky
NV16-31643A
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
NLK
Free Medical Journals
od 2009
PubMed Central
od 2009
Europe PubMed Central
od 2009
ProQuest Central
od 2009-01-01
Open Access Digital Library
od 2009-01-01
Open Access Digital Library
od 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2009
PubMed
32365651
DOI
10.3390/cancers12051115
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
The quality of pathological assessment is crucial for the safety of patients with cervical cancer if pelvic lymph node dissection is to be replaced by sentinel lymph node (SLN) biopsy. Central pathology review of SLN pathological ultrastaging was conducted in the prospective SENTIX/European Network of Gynaecological Oncological Trial (ENGOT)-CX2 study. All specimens from at least two patients per site were submitted for the central review. For cases with major or critical deviations, the sites were requested to submit all samples from all additional patients for second-round assessment. From the group of 300 patients, samples from 83 cases from 37 sites were reviewed in the first round. Minor, major, critical, and no deviations were identified in 28%, 19%, 14%, and 39% of cases, respectively. Samples from 26 patients were submitted for the second-round review, with only two major deviations found. In conclusion, a high rate of major or critical deviations was identified in the first round of the central pathology review (28% of samples). This reflects a substantial heterogeneity in current practice, despite trial protocol requirements. The importance of the central review conducted prospectively at the early phase of the trial is demonstrated by a substantial improvement of SLN ultrastaging quality in the second-round review.
Center for Gynecologic Oncology Academic Medical Centre 1100DD Amsterdam The Netherlands
Department of Gynaecology St Olav's Hospital 7006 Trondheim Norway
Department of Gynecologic Oncology Holycross Cancer Center 25 734 Kielce Poland
Department of Gynecology and Obstetrics Hospital Clinico San Carlos 28040 Madrid Spain
Department of Gynecology and Obstetrics Hospital Español de Buenos Aires Buenos Aires 2975 Argentina
Department of Gynecology Francisco Gentil Portuguese Oncology Institute 4200 072 Porto Portugal
Department of Gynecology Medical Faculty University of Cologne 50937 Cologne Germany
Department of Obstetrics and Gynecology Cantonal Hospital of Lucerne 6000 Lucerne Switzerland
Department of Obstetrics and Gynecology Faculty Hospital Trencin 91171 Trencin Slovakia
Department of Obstetrics and Gynecology Institute of Mother and Child 01 211 Warsaw Poland
Gynecology Department Instituto Valenciano de Oncología 46009 Valencia Spain
IRCCS Foundation National Cancer Institute in Milan 20133 Milan Italy
KNTB a s 762 75 Zlin Czech Republic
LISOD Israeli Oncological Hospital 08720 Plyuty Ukraine
MD Anderson Cancer Center 28033 Madrid Spain
Medical University of Graz 8036 Graz Austria
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20019268
- 003
- CZ-PrNML
- 005
- 20201123123749.0
- 007
- ta
- 008
- 201103s2020 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/cancers12051115 $2 doi
- 035 __
- $a (PubMed)32365651
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Nemejcova, Kristyna $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital, 12000 Prague, Czech Republic.
- 245 10
- $a Central Pathology Review in SENTIX, A Prospective Observational International Study on Sentinel Lymph Node Biopsy in Patients with Early-Stage Cervical Cancer (ENGOT-CX2) / $c K. Nemejcova, R. Kocian, C. Kohler, J. Jarkovsky, J. Klat, A. Berjon, R. Pilka, B. Sehnal, B. Gil-Ibanez, E. Lupo, A. Petiz, OA. Sanchez, P. Kascak, F. Martinelli, A. Buda, J. Presl, M. Barahona, LV. Lonkhuijzen, W. Szatkowski, L. Minar, M. Pakiz, P. Havelka, C. Zorrero, M. Misiek, LC. Snyman, D. Wydra, I. Vergote, A. Vinnytska, M. Redecha, M. Michal, S. Tingulstad, B. Kipp, G. Szewczyk, R. Toth, FJS. Garcia, PJC. Martin, R. Poka, K. Tamussino, M. Luyckx, M. Fastrez, JC. Staringer, A. Germanova, A. Plaikner, S. Bajsova, P. Dundr, N. Mallmann-Gottschalk, D. Cibula,
- 520 9_
- $a The quality of pathological assessment is crucial for the safety of patients with cervical cancer if pelvic lymph node dissection is to be replaced by sentinel lymph node (SLN) biopsy. Central pathology review of SLN pathological ultrastaging was conducted in the prospective SENTIX/European Network of Gynaecological Oncological Trial (ENGOT)-CX2 study. All specimens from at least two patients per site were submitted for the central review. For cases with major or critical deviations, the sites were requested to submit all samples from all additional patients for second-round assessment. From the group of 300 patients, samples from 83 cases from 37 sites were reviewed in the first round. Minor, major, critical, and no deviations were identified in 28%, 19%, 14%, and 39% of cases, respectively. Samples from 26 patients were submitted for the second-round review, with only two major deviations found. In conclusion, a high rate of major or critical deviations was identified in the first round of the central pathology review (28% of samples). This reflects a substantial heterogeneity in current practice, despite trial protocol requirements. The importance of the central review conducted prospectively at the early phase of the trial is demonstrated by a substantial improvement of SLN ultrastaging quality in the second-round review.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kocian, Roman $u Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital, 12000 Prague, Czech Republic.
- 700 1_
- $a Kohler, Christhardt $u Department of Special Operative and Oncologic Gynaecology, Asklepios-Clinic Hamburg, 22763 Hamburg, Germany.
- 700 1_
- $a Jarkovsky, Jiri $u Institute for Biostatistics and Analyses, Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic.
- 700 1_
- $a Klat, Jaroslav $u Department of Obstetrics and Gynecology, University Hospital Ostrava, 708 52 Ostrava Poruba, Czech Republic.
- 700 1_
- $a Berjon, Alberto $u Department of Pathology, La Paz University Hospital, 28046 Madrid, Spain. Molecular Pathology and Therapeutic Targets Group, IdiPAZ, 28046 Madrid, Spain.
- 700 1_
- $a Pilka, Radovan $u Department of Obstetrics and Gynecology, Faculty of Medicine and Dentistry, Palacky University, University Hospital Olomouc, 77520 Olomouc, Czech Republic.
- 700 1_
- $a Sehnal, Borek $u Department of Obstetrics and Gynecology, Bulovka Hospital, First Faculty of Medicine, Charles University, 18081 Prague, Czech Republic.
- 700 1_
- $a Gil-Ibanez, Blanca $u Unit of Gynecological Oncology, Institute Clinic of Gynecology, Obstetrics and Neonatology (ICGON), Hospital Clinic of Barcelona, 08036 Barcelona, Spain.
- 700 1_
- $a Lupo, Ezequiel $u Department of Pathology, Institute of Oncology Angel H. Roffo, University of Buenos Aires, Buenos Aires Autonomous City 1214, Argentina.
- 700 1_
- $a Petiz, Almerinda $u Department of Gynecology, Francisco Gentil Portuguese Oncology Institute, 4200-072 Porto, Portugal.
- 700 1_
- $a Sanchez, Octavio Arencibia $u Departments of Gynecologic Oncology, University Hospital of the Canary Islands, 35016 Las Palmas de Gran Canaria, Spain.
- 700 1_
- $a Kascak, Peter $u Department of Obstetrics and Gynecology, Faculty Hospital Trencin, 91171 Trencin, Slovakia.
- 700 1_
- $a Martinelli, Fabio $u IRCCS Foundation National Cancer Institute in Milan, 20133 Milan, Italy.
- 700 1_
- $a Buda, Alessandro $u Department of Obstetrics and Gynecology, Unit of Gynecologic Oncology Surgery, San Gerardo Hospital, 20900 Monza, Italy.
- 700 1_
- $a Presl, Jiri $u Department of Gynaecology and Obstetrics, University Hospital Pilsen, Charles University, 30460 Prague, Czech Republic.
- 700 1_
- $a Barahona, Marc $u Department of Gynecology, University Hospital of Bellvitge, Biomedical Research Institute of Bellvitge, University of Barcelona, 08907 Barcelona, Spain.
- 700 1_
- $a Lonkhuijzen, Luc van $u Center for Gynecologic Oncology, Academic Medical Centre, 1100DD Amsterdam, The Netherlands.
- 700 1_
- $a Szatkowski, Wiktor $u Department of Gynecologic Oncology, Centre of Oncology, M. Sklodowska-Curie Memorial Institute, Cracow Department, 31-115 Cracow, Poland.
- 700 1_
- $a Minar, Lubos $u Department of Gynecology and Obstetrics, Faculty of Medicine, Masaryk University, 60200 Brno, Czech Republic.
- 700 1_
- $a Pakiz, Maja $u University Clinic for Gynaecology and Perinatology, University Medical Centre Maribor, 2000 Maribor, Slovenia.
- 700 1_
- $a Havelka, Pavel $u KNTB a.s, 762 75 Zlin, Czech Republic.
- 700 1_
- $a Zorrero, Cristina $u Gynecology Department, Instituto Valenciano de Oncología (IVO), 46009 Valencia, Spain.
- 700 1_
- $a Misiek, Marcin $u Department of Gynecologic Oncology, Holycross Cancer Center, 25-734 Kielce, Poland.
- 700 1_
- $a Snyman, Leon Cornelius $u Gynaecologic Oncology Unit, Department of Obstetrics and Gynaecology, University of Pretoria, Pretoria 0001, South Africa.
- 700 1_
- $a Wydra, Dariusz $u Department of Gynecology, Gynecologic Oncology and Gynecologic Endocrinology, Medical University of 80-402 Gdansk, Poland.
- 700 1_
- $a Vergote, Ignace $u Department of Gynecology and Obstetrics, University Hospital Leuven, Leuven Cancer Institute, 3000 Leuven, Belgium.
- 700 1_
- $a Vinnytska, Alla $u LISOD - Israeli Oncological Hospital, 08720 Plyuty, Ukraine.
- 700 1_
- $a Redecha, Mikulas $u Department of Gynaecology and Obstetrics, University Hospital, Comenius University, 82101 Bratislava, Slovakia.
- 700 1_
- $a Michal, Martin $u Department of Obstetrics and Gynaecology, Hospital Ceske Budejovice, JSC, 37001 Ceske Budejovice, Czech Republic.
- 700 1_
- $a Tingulstad, Solveig $u Department of Gynaecology, St Olav's Hospital, 7006 Trondheim, Norway.
- 700 1_
- $a Kipp, Barbara $u Department of Obstetrics and Gynecology, Cantonal Hospital of Lucerne, 6000 Lucerne, Switzerland.
- 700 1_
- $a Szewczyk, Grzegorz $u Department of Obstetrics and Gynecology, Institute of Mother and Child, 01-211 Warsaw, Poland.
- 700 1_
- $a Toth, Robert $u Oncology Institute of East Slovakia, 04191 Košice, Slovakia.
- 700 1_
- $a Garcia, Francisco Javier de Santiago $u MD Anderson Cancer Center, 28033 Madrid, Spain.
- 700 1_
- $a Martin, Pluvio Jesus Coronado $u Department of Gynecology and Obstetrics, Hospital Clinico San Carlos, 28040 Madrid, Spain.
- 700 1_
- $a Poka, Robert $u Institute of Obstetrics and Gynaecology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
- 700 1_
- $a Tamussino, Karl $u Medical University of Graz, 8036 Graz, Austria.
- 700 1_
- $a Luyckx, Mathieu $u Department of Gynecology, Universite catholique de Louvain, Cliniques Universitaires St Luc, 1200 Brussels, Belgium.
- 700 1_
- $a Fastrez, Maxime $u Department of Obstetrics and Gynaecology, St Pierre University Hospital, Universite Libre de Bruxelles, 1000 Brussels, Belgium.
- 700 1_
- $a Staringer, Juan Carlos $u Department of Gynecology and Obstetrics, Hospital Español de Buenos Aires, Buenos Aires 2975, Argentina.
- 700 1_
- $a Germanova, Anna $u Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital, 12000 Prague, Czech Republic.
- 700 1_
- $a Plaikner, Andrea $u Department of Special Operative and Oncologic Gynaecology, Asklepios-Clinic Hamburg, 22763 Hamburg, Germany.
- 700 1_
- $a Bajsova, Sylva $u Department of Obstetrics and Gynecology, University Hospital Ostrava, 708 52 Ostrava Poruba, Czech Republic.
- 700 1_
- $a Dundr, Pavel $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital, 12000 Prague, Czech Republic.
- 700 1_
- $a Mallmann-Gottschalk, Nina $u Department of Gynecology, Medical Faculty, University of Cologne, 50937 Cologne, Germany.
- 700 1_
- $a Cibula, David $u Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital, 12000 Prague, Czech Republic.
- 773 0_
- $w MED00173178 $t Cancers $x 2072-6694 $g Roč. 12, č. 5 (2020)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32365651 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201103 $b ABA008
- 991 __
- $a 20201123123748 $b ABA008
- 999 __
- $a ind $b bmc $g 1586046 $s 1109466
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 12 $c 5 $e 20200429 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
- GRA __
- $a Project RVO 64165 $p Ministry of Health, Czech Republic
- GRA __
- $a No 16-31643A $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a NV19-03-00023 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a NV16-31643A $p MZ0
- LZP __
- $a Pubmed-20201103
